1 According to Novo Nordisk, these medications will be provided to US consumers at the same affordable self-pay prices as other telehealth platforms
The greatest growth among GLP-1 receptor agonists in prescriptions for patients with type 1 diabetes occurred with semaglutide (Ozempic/Rybelsus/Wegovy, Novo Nordisk), which rose from 0.2% in 2018 to 4.4% in 2023, whereas tirzepatide (Mounjaro/Zepbound, Eli Lilly) was prescribed in 1.3% of patients with type 1 diabetes in 2023 after being introduced in 2022
To evaluate the convergence of published results, we first conduct a multi-level kernel density meta-analysis of studies reporting a positive association of ghrelin ( N comb = 353, 18 contrasts) and a negative association of GLP-1 ( N comb = 258, 12 contrasts) and reward responses measured using task functional magnetic resonance imaging (fMRI)
Maintain precise timing, accurate dosing, and supportive nutrition
Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, et al
Patients should be counseled on strategies to minimize these effects, including eating smaller meals, avoiding high-fat foods, and maintaining adequate hydration